Timing and Order of Thrombolytics and Low Molecular Weight Heparin for Pulmonary Embolism

Treatment Algorithm Based on PE Severity

The European Society of Cardiology recommends administering systemic thrombolytic therapy immediately upon diagnosis for patients with high-risk pulmonary embolism, followed by anticoagulation with low molecular weight heparin (LMWH) after the thrombolytic effect has been established, typically waiting at least 1-2 hours after completion of thrombolytic therapy before initiating LMWH 1, 2
For high-risk pulmonary embolism patients, the American College of Chest Physicians suggests waiting at least 1-2 hours after completion of thrombolytic therapy before initiating anticoagulation with LMWH, to minimize the risk of bleeding 3, 2
The European Society of Cardiology recommends starting LMWH or unfractionated heparin (UFH) after thrombolysis when bleeding risk is acceptable, for patients with high-risk pulmonary embolism 1, 4

The European Respiratory Society suggests that for high-risk pulmonary embolism patients receiving thrombolysis, the thrombolytic agent should be administered first to rapidly restore pulmonary circulation, followed by anticoagulation with LMWH after the thrombolytic effect has been established 2, 4
The European Society of Cardiology recommends delaying anticoagulation with LMWH until the thrombolytic effect has been established and risk of bleeding is acceptable, for patients with high-risk pulmonary embolism receiving thrombolysis 3, 2

The European Society of Cardiology recommends low molecular weight heparin (LMWH) over unfractionated heparin (UFH) for most patients with pulmonary embolism, except in cases of severe renal impairment or when thrombolysis is being considered 1, 5
The American College of Chest Physicians suggests that for patients eligible for novel oral anticoagulants (NOACs), transition from parenteral anticoagulation to NOAC therapy can occur after 1-2 days of parenteral treatment, but this is based on a lower level of evidence 7

The European Society of Cardiology recommends that all patients with pulmonary embolism should receive therapeutic anticoagulation for at least 3 months, with a strength of evidence rated as high 1, 6